Breaking News Instant updates and real-time market news.

BAC

Bank of America

$20.30

-0.56 (-2.68%)

, AAPL

Apple

$111.57

-0.22 (-0.20%)

08:55
11/29/16
11/29
08:55
11/29/16
08:55

Notable open interest changes for November 29th

Monday's total option volume of 13.8 million contracts resulted in net open interest growth of 2.48 million calls and 3.08 million puts. Bank of America (BAC), Apple (AAPL), Vale (VALE) and AstraZeneca (AZN) saw the greatest growth. Top five new positions opened include 28k Apple (AAPL) Jan-18 100 calls, 27k ArcelorMittal (MT) Dec-16 8 calls, 21k AstraZeneca (AZN) Jul-17 30 calls, 20k AstraZeneca (AZN) Jul-17 32.5 calls and 19k Dynavax (DVAX) Jan-17 18 calls.

BAC

Bank of America

$20.30

-0.56 (-2.68%)

AAPL

Apple

$111.57

-0.22 (-0.20%)

VALE

Vale

$9.10

0.68 (8.08%)

AZN

AstraZeneca

$26.73

-0.37 (-1.37%)

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 13

    Jan

  • 16

    Feb

BAC Bank of America
$20.30

-0.56 (-2.68%)

11/16/16
11/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Sysco (SYY) downgraded to Neutral from Outperform at Credit Suisse with analyst Edward Kelly saying Sysco shares are up 50% over the last 18 months and now views risk/reward as balanced. 2. Teva (TEVA) downgraded to Hold from Buy at Jefferies, to Equal Weight from Overweight at Morgan Stanley, and to Neutral from Buy at BTIG. 3. Bank of America (BAC) Capital One (COF) downgraded to Neutral from Outperform at Baird while the firm downgraded Fifth Third (FITB) to Underperform from Neutral. 4. Zions Bancorp (ZION) downgraded to Equal Weight from Overweight at Morgan Stanley and to Market Perform from Outperform at Bernstein. 5. Yingli Green Energy (YGE) downgraded to Sell from Buy at Axiom while the firm downgraded SolarCity (SCTY) and JA Solar (JASO) to Sell from Hold. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/16
11/16/16
DOWNGRADE
Target $18

Neutral
Bank of America downgraded to Neutral from Outperform at Baird
As previously reported, Baird analyst David George downgraded Bank of America to Neutral from Buy as he believes the post-election rally has largely discounted the potential benefits of rising interest rates, lower taxes, and more aggressive capital return. George raised his price target to $18 from $17 on Bank of America shares.
11/16/16
BARD
11/16/16
DOWNGRADE
BARD
Neutral
Bank of America downgraded to Neutral from Outperform at Baird
11/29/16
KBWI
11/29/16
UPGRADE
Target $23
KBWI
Outperform
Bank of America upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded Bank of America to Outperform citing expectations for improved operating and regulatory environments. The valuation remains reasonable despite the recent rally, Kleinhanzl tells investors in a research note. The analyst raised his price target for the shares to $23 from $17.50.
AAPL Apple
$111.57

-0.22 (-0.20%)

11/21/16
ADAM
11/21/16
NO CHANGE
Target $140
ADAM
Buy
Apple continues to dominate industry operating profits, says Canaccord
Canaccord analyst T. Michael Walkley said Apple captured a strong share of the premium-tier global smartphone market during Q3 and believes they will continue to extend their leading market share position. He noted Apple will continue to generate strong profit share despite iPhone sales moderating in North America over the past several weeks. Walkley expects steady iPhone 7 sales will help Apple return to growth in Q1 2017 and reiterated his Buy rating and $140 price target on the shares.
11/23/16
CLVD
11/23/16
NO CHANGE
CLVD
Neutral
Apple iPhone 7 supply remains constrained, says Cleveland Research
Cleveland Research said its near-term work remains encouraging on iPhone 7 demand and mix, with checks indicating that supply of iPhone 7 seems to be normalizing in most channels and tightness persists for the 7+. Discussions also suggest growing optimism for the next iPhone refresh, said the firm, which has a Neutral rating on Apple shares.
11/23/16
RSBL
11/23/16
NO CHANGE
RSBL
Apple trimming March quarter component order forecast, says Rosenblatt
Rosenblatt believes Apple has starting trimming its March quarter component order forecast following last week's December quarter production cut. The firm's analyst now expects orders to drop to 40M-43M units from 45M-46M, and believes March quarter's iPhone shipment consensus forecast of 52M-54M may be at risk.
11/29/16
UBSW
11/29/16
NO CHANGE
Target $127
UBSW
Buy
Apple procurement estimates suggest risk to next two quarters, says UBS
UBS analyst Steven Milunovich said Apple's procurement numbers for the December and March quarters have been revised downward, putting consensus estimates for the two quarters at risk. The analyst is leaving his estimates unchanged, but notes his view remains below consensus. He said many investors are looking to 2018, when high retention rates and an aging installed base could drive significant upgrades for the next iteration of the iPhone. Milunovich reiterated his Buy rating and $127 price target on Apple shares.
VALE Vale
$9.10

0.68 (8.08%)

09/12/16
JPMS
09/12/16
UPGRADE
Target $7
JPMS
Overweight
Vale upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Rodolfo Angele upgrade Vale to Overweight saying he now expects the company to post positive free cash flow in 2017 and beyond amid more supportive iron ore prices. The analyst raised his price target for the shares to $7 from $5.
09/21/16
LEHM
09/21/16
UPGRADE
Target $4
LEHM
Equal Weight
Vale upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Amos Fletcher upgraded Vale to Equal Weight with a $4 price target.
10/20/16
IBBA
10/20/16
UPGRADE
IBBA
Outperform
Vale upgraded to Outperform from Market Perform at Itau BBA
11/01/16
SBSH
11/01/16
UPGRADE
SBSH
Neutral
Vale upgraded to Neutral from Sell at Citi
AZN AstraZeneca
$26.73

-0.37 (-1.37%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.

TODAY'S FREE FLY STORIES

VRX

Valeant

$17.15

0.5 (3.00%)

06:40
06/29/17
06/29
06:40
06/29/17
06:40
Technical Analysis
Technical View: Valeant moves higher in early trading »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

, BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

06:38
06/29/17
06/29
06:38
06/29/17
06:38
Hot Stocks
Home Capital gets TSX approval for equity investment by Berkshire Hathaway »

Home Capital Group is…

BRK.A

Berkshire Hathaway

$254,660.00

3350 (1.33%)

BRK.B

Berkshire Hathaway

$169.89

2.54 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNRO

Monro Muffler

$41.70

-3.45 (-7.64%)

06:36
06/29/17
06/29
06:36
06/29/17
06:36
Downgrade
Monro Muffler rating change  »

Monro Muffler downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFS

CHF Solutions

$0.62

-0.0074 (-1.17%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Initiation
CHF Solutions initiated  »

CHF Solutions initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$98.95

0.42 (0.43%)

06:33
06/29/17
06/29
06:33
06/29/17
06:33
Earnings
McCormick backs FY17 adj. EPS view of $4.05-$4.13 »

Sees FY17 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

MKC

McCormick

$98.95

0.42 (0.43%)

06:31
06/29/17
06/29
06:31
06/29/17
06:31
Earnings
McCormick reports Q2 adj. EPS 82c, consensus 76c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

PIR

Pier 1 Imports

$5.38

0.04 (0.75%)

06:25
06/29/17
06/29
06:25
06/29/17
06:25
Recommendations
Pier 1 Imports analyst commentary  »

Pier 1 Imports shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

06:22
06/29/17
06/29
06:22
06/29/17
06:22
Recommendations
Weibo analyst commentary  »

Weibo content block to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$69.36

0.28 (0.41%)

, SINA

SINA

$86.75

1.78 (2.09%)

06:18
06/29/17
06/29
06:18
06/29/17
06:18
Periodicals
China's Weibo to block unlicensed video conternt, Reuters reports »

China's Weibo (WB)…

WB

Weibo

$69.36

0.28 (0.41%)

SINA

SINA

$86.75

1.78 (2.09%)

FENG

Phoenix New Media

$2.70

-0.04 (-1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$27.83

-0.35 (-1.24%)

06:13
06/29/17
06/29
06:13
06/29/17
06:13
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$37.89

0.65 (1.75%)

06:10
06/29/17
06/29
06:10
06/29/17
06:10
Recommendations
Allison Transmission analyst commentary  »

Piper 'growing more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$27.69

1.13 (4.25%)

06:05
06/29/17
06/29
06:05
06/29/17
06:05
Hot Stocks
Noah Holdings authorizes $50M share repurchase program »

Noah Holdings has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Earnings
Greenbrier sees FY17 EPS $3.45-$3.65, consensus $3.49 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

PDS

Precision Drilling

$3.36

0.03 (0.90%)

06:04
06/29/17
06/29
06:04
06/29/17
06:04
Downgrade
Precision Drilling rating change  »

Precision Drilling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$50.00

0.55 (1.11%)

06:03
06/29/17
06/29
06:03
06/29/17
06:03
Earnings
Greenbrier reports Q3 EPS $1.03, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 07

    Jul

SPX

S&P 500

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.00

0.46 (7.03%)

06:01
06/29/17
06/29
06:01
06/29/17
06:01
Recommendations
ImmunoGen analyst commentary  »

ImmunoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$22.43

0.17 (0.76%)

05:58
06/29/17
06/29
05:58
06/29/17
05:58
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.90

0.09 (0.08%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.99

0.49 (1.56%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$19.69

0.8 (4.24%)

05:57
06/29/17
06/29
05:57
06/29/17
05:57
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUST

Direxion Daily Gold Miners Bear 3X ETF

$29.70

-0.63 (-2.08%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Gold Miners Bear 3X ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JDST

Direxion Daily Junior Gold Miners Index Bear 3x Shares

$60.67

-2.77 (-4.37%)

05:56
06/29/17
06/29
05:56
06/29/17
05:56
Technical Analysis
Direxion Daily Junior Gold Miners Index Bear 3x Shares: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VXX

iPath S&P 500 VIX Short-Term Futures

$12.33

-0.34 (-2.68%)

05:49
06/29/17
06/29
05:49
06/29/17
05:49
Technical Analysis
iPath S&P 500 VIX Short-Term Futures: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XIV

VelocityShares Daily Inverse VIX Short-Term ETN

$86.47

2.38 (2.83%)

05:49
06/29/17
06/29
05:49
06/29/17
05:49
Technical Analysis
VelocityShares Daily Inverse VIX Short-Term ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.